Co-administration of the EGFR monoclonal antibody cetuximab enhances cellular sensitivity to MRTX1133, inducing tumor regression in KRAS G12D-mutant xenograft models (Hallin et al., 2022). This evidence concerns the gene KRAS and neoplasm.